CSL Ltd

Parkville, Australia
Parkville, Australia

Time filter

Source Type

Patent
CSL Ltd and A+ Network | Date: 2016-08-10

A method for inhibition of leukemic stem cells expressing IL-3R (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.


Patent
CSL Behring GmbH and CSL Ltd. | Date: 2016-11-04

The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.


Patent
CSL Behring GmbH and CSL Ltd. | Date: 2016-11-04

The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.


The present invention relates to improved methods for the recombinant production of von Willebrand factor (vWF) in a bioreactor by separating different multimeric forms of vWF with different molecular weight during fermentation.


The present invention relates to dosing regimens with half-life extended Factor VIIa (FVIIa) for prophylactic and on-demand treatment of bleeding, as well as for preventing a bleeding episode during or after surgery in patients with congenital or acquired bleeding disorders. The present invention further relates to the use of half-life extended FVIIa for treating or preventing blood loss in patients without bleeding disorders in situations of hemorrhage i.e., due to trauma or surgery. Another aspect of the invention is the treatment of acquired haemophilia.


A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAl or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.


Patent
CSL Ltd | Date: 2017-06-14

The invention relates to factor VIII compositions and their use.


Patent
CSL Ltd | Date: 2017-05-10

The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least a modification at position 1 or 3 such that the modified polypeptide binds to Factor VIII with an off rate at least 5 fold lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.


A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.


Patent
CSL Ltd | Date: 2017-04-18

The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.

Loading CSL Ltd collaborators
Loading CSL Ltd collaborators